A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Clinical trial NCT07103486 · COMPLETED
Trial details
- NCT number
- NCT07103486
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2021-04-01
- Primary completion
- 2023-01-31
- Enrollment
- 264
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.